Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) \
3 min read
\
\

Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®)

15-Sep-2021
Mumbai (Maharashtra) [India], September 15 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced the successful completion of its Post Marketing Surveillance (PMS) study on Favipiravir (FabiFlu®) in India.
15-Sep-2021 Business
\